Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

First must come treatment for covid-19 patients in the coming weeks. Most immediately, NIAID and CDC will examine current status of safety. If there is sufficient proof, then it will almost immediately be used on patients in a real-time, in-field assessment. Patients not treated with B will serve as real-time, authentic, clinical practice controls. Efficacy will be measured against those not treated or treated with other drugs.

Emergency measures testing differs from vaccine testing in that no vaccine is ever tested in field until safety is established, even under emergency measures. The CDC learned its lesson during the deadly swine flu outbreak in the 70’s. The Swine Flu vaccine was rushed into use with minimum safety tests. People died from the vaccine. That’s why there will be no covid-19 vaccine for at least 12 months and more likely 18.

In any case, we will know if B is effective against coronavirus symptoms long before a vaccine is available. Outcomes will include measurable reduction in severity of symptoms, reduction in secondary infections, reduction of swelling and damage to alveoli, reduction in recovery time. If it meets any combination of those outcomes, testing and use will be expanded.